A Phase 1, Open-Label, Randomized, 2-Period Crossover Study To Evaluate The Effect Of Food On AG-120 Pharmacokinetics Following Single Oral Dose Administration To Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 01 Dec 2016
At a glance
- Drugs Ivosidenib (Primary)
- Indications Acute myeloid leukaemia; Glioma; Myelodysplastic syndromes; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Agios Pharmaceuticals
- 28 Nov 2016 Status changed from active, no longer recruiting to completed.
- 27 Apr 2016 Planned End Date changed from 1 Mar 2016 to 1 Jun 2016.
- 11 Dec 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.